21 – 30 of 659
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
- Contribution to journal › Article
-
Mark
Sicklecellsjukdom - vanliga och farliga komplikationer
- Contribution to journal › Article
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
- Contribution to journal › Article
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
- Contribution to journal › Debate/Note/Editorial
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
- Contribution to journal › Article
-
Mark
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
(2024) In Haemophilia
- Contribution to journal › Article
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
- Contribution to journal › Article
-
Mark
SERPINH1 variants and thrombotic risk among middle-aged and older adults : a population-based cohort study
- Contribution to journal › Letter
-
Mark
Haemophilia A - In pursuit of optimised outcomes via personalised treatment
(2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
Historical perspective on von Willebrand disease
(2024) p.1-6
- Chapter in Book/Report/Conference proceeding › Book chapter
